RT Journal Article SR Electronic T1 177Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 809 OP 814 DO 10.2967/jnumed.117.193847 VO 59 IS 5 A1 Baum, Richard P. A1 Singh, Aviral A1 Schuchardt, Christiane A1 Kulkarni, Harshad R. A1 Klette, Ingo A1 Wiessalla, Stefan A1 Osterkamp, Frank A1 Reineke, Ulrich A1 Smerling, Christiane YR 2018 UL http://jnm.snmjournals.org/content/59/5/809.abstract AB Neurotensin receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the deadliest cancers, with a very poor prognosis. Eligible patients were offered salvage radiopharmaceutical therapy with the novel NTR1 antagonist 177Lu-3BP-227. Methods: Six patients with confirmed ductal pancreatic adenocarcinoma who had exhausted all other treatment options received 177Lu-3BP-227 for evaluation of NTR1 expression in vivo. Three patients received treatment activities of 5.1–7.5 GBq. Results: Administration of 177Lu-3BP-227 was well tolerated by all patients. The kidneys were identified as the dose-limiting organ. The most severe adverse event was reversible grade 2 anemia. One patient achieved a partial response and experienced significant improvement of symptoms and quality of life. This patient survived 13 mo from diagnosis and 11 mo from the start of 177Lu-3BP-227 therapy. Conclusion: This initial report provides clinical evidence of the feasibility of treatment of ductal pancreatic adenocarcinoma using 177Lu-3BP-227.